What this study is
This study evaluates how new magnetic resonance imaging (MRI) and artificial intelligence techniques improve the image quality and quantitative information for future prostate MRI exams in patients with suspicious of confirmed prostate cancer. The MRI and artificial intelligence techniques developed in this study may improve the accuracy in diagnosing prostate cancer in the future using less invasive techniques than what is currently used.
What's being tested
- 3 Tesla Magnetic Resonance Imaging
Intervention · PROCEDURE
Undergo 3T MRI
- Electronic Health Record Review
Intervention · OTHER
Medical charts are reviewed
Study details
- Sponsor
- Jonsson Comprehensive Cancer Center
- Conditions
- Prostate Carcinoma
- Enrolling
- 275 people
- Starts
- 2021-04-01
- Est. completion
- 2028-06-01
- Record
- View on ClinicalTrials.gov ↗
Who can join
Age 18 Years and overSex MALEHealthy volunteers Not acceptedYou may qualify if
- Male patients 18 years of age and older
- Clinical suspicion of prostate cancer or biopsy-confirmed prostate cancer
- Undergone or undergoing multi-parametric 3 T prostate MRI at the University of California at Los Angeles (UCLA)
- Ability to provide consent
You can't join if
- Contraindications to MRI (e.g., cardiac devices, prosthetic valves, severe claustrophobia)
- Contraindications to gadolinium contrast-based agents other than the possibility of an allergic reaction to the gadolinium contrast-based agent
- Prior radiotherapy
Sign in and we'll check these against your records.Full criteria on ClinicalTrials.gov ↗
Loading treatment details…
Study locations (1)
1 openUCLA / Jonsson Comprehensive Cancer Center
Los Angeles, California, United States
- Nashla Barroso · Contact310-794-7952nbarroso@mednet.ucla.edu
- Kyung H. Sung, PhD · Principal investigator
Recruiting
Study team
Sponsor
Jonsson Comprehensive Cancer Center
Study ID 19-002202
Principal investigator
Kyung H Sung, PhD
UCLA / Jonsson Comprehensive Cancer Center
Frequently asked questions
The sponsor hasn't published answers to common questions for this trial.